What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Massimo Cajozzo, Eugenio Fiorentino, Giuseppe Bronte, Antonio Russo, Francesco Passiglia, Ignacio Gil-Bazo, Patrick Pauwels, Christian Rolfo, Jan P. Van Meerbeeck, Cosimo Lequaglie, Daniele Santini, Christian Diego Rolfo, Sergio Rizzo

Risultato della ricerca: Article

17 Citazioni (Scopus)


BackgroundRandomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.Materials and methodsData from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities.ResultsSix eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group.ConclusionThis meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
Lingua originaleEnglish
pagine (da-a)306-317
Numero di pagine12
Stato di pubblicazionePublished - 2015


All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

Cajozzo, M., Fiorentino, E., Bronte, G., Russo, A., Passiglia, F., Gil-Bazo, I., Pauwels, P., Rolfo, C., Van Meerbeeck, J. P., Lequaglie, C., Santini, D., Rolfo, C. D., & Rizzo, S. (2015). What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 95, 306-317.